Radient Pharmaceuticals (RPC) Reports Q1 Loss of $0.13, Revenue Falls Y/Y
Tweet
Share
E-mailGet Alerts RPC Hot Sheet
Join SI Premium – FREE
Radient Pharmaceuticals (NYSE: RPC) reported Q1 EPS of ($0.13), versus ($0.10) reported last year. Revenue for the quarter came in at $30.66 million, versus $36.85 million reported last year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ridgepost Capital Announces Appointment of Vice President, Investor Relations
- Oxford Industries (OXM) Tops Q1 EPS by 12c; Offers Outlook
- McGraw Hill (MH) Tops Q1 EPS by 15c, Beats on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
